首页

Zhaoke Ophthalmology Partners with AFT Pharmaceuticals Limited To Commercialize BRIMOCHOLTM PF In Australia and New Zealand

2025-01-13

178

Zhaoke Ophthalmology Obtains Regulatory Acceptance of its Abbreviated New Drug Application for NVK002 for Myopia Progression Control in Children

2025-01-02

223

Zhaoke Ophthalmology Achieves Positive Topline Results from the Phase III Clinical Trial of TAB014 for wAMD

2025-01-02

412

Zhaoke Ophthalmology Receives Regulatory Approval to Commercialize Three further Drugs in its Glaucoma Portfolio

2024-12-09

483

Zhaoke Ophthalmology Achieves Positive Topline Results from the Two-Year Phase III Clinical Trial of its Myopia Drug NVK002

2024-10-23

1183

首页 1 2 3 4 5 尾页

Guangzhou Headquarters

Tel: 020-39062828

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat

Guangzhou Headquarters

Tel: 020-39062888

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

Wechat